Clinical Cancer Research CR Helping Patients Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 7506, December 15, 2007. doi: 10.1158/1078-0432.CCR-07-0457
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rokavec, M.
Right arrow Articles by Brauch, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rokavec, M.
Right arrow Articles by Brauch, H.

Cancer Susceptibility and Prevention

A Novel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk

Matjaz Rokavec1,2,3, Christina Justenhoven1,2, Werner Schroth1,2, Monica Adina Istrate1,2, Susanne Haas4, Hans-Peter Fischer4, Caren Vollmert5, Thomas Illig5, Ute Hamann6, Yon-Dschun Ko7, Damjan Glavac3 and Hiltrud Brauch1,2

Authors' Affiliations: 1 Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; 2 Department of Clinical Pharmacology University Tübingen, Tübingen, Germany; 3 Department of Molecular Genetics, Institute of Pathology, Medical Faculty, University of Ljubljana, Slovenia; 4 Institute of Pathology, Medical Faculty of the University of Bonn, Germany; 5 GSF-National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg, Germany; 6 Deutsches Krebsforschungszentrum, Heidelberg, Germany; and 7 Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus Bonn, Germany

Requests for reprints: Hiltrud Brauch, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany. Phone: 49-711-8101-3705; Fax: 49-711-85-9295; E-mail: hiltrud.brauch{at}ikp-stuttgart.de.

Purpose: The receptor tyrosine kinase ERBB4/HER4 plays a role in cell division, migration, differentiation, as well as apoptosis, and is frequently overexpressed in breast and colorectal tumors. To understand the role of genetic variations in the regulation of ERBB4 expression, we identified new polymorphisms and investigated their functional implication and risk association with breast and colorectal cancer.

Experimental Design: We screened colorectal tumors from 92 patients for genetic variants at the ERBB4 ATG –1000 bp 5'-regulatory region by denaturing high-performance liquid chromatography and sequencing. Variants were subjected to DNA-protein interaction analyses (electrophoretic mobility shift assay), reporter gene assays in breast cancer cell lines MDA134 and MDA157, and immunohistochemical analyses of breast tumors. We established genotype frequencies within a breast cancer case-control collection (1,021 cases, 1,015 population-based controls) and a colorectal cancer case-control collection (459 cases, 569 blood donors) using matrix-assisted laser desorption ionization/time of flight mass spectrometry. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were assessed by multivariate logistic regression.

Results: We identified five new germ line variants –815 A>T, –782 G>T, –638 insTC, –267 C>G, and –219 del10bp. Two variants showed in vitro functional effects. The –782T allele showed lower protein binding affinity and lower promoter activity compared with the –782G allele, however, the –815T allele showed higher protein binding affinity and higher promoter activity. The –782T variant was identified as a risk allele for breast and colorectal cancer (OR, 1.59; 95% CI, 1.06-2.34 and OR, 2.21; 95% CI, 1.22-3.99, respectively).

Conclusion: The ERBB4 –782 G>T polymorphism, by virtue of its in vitro functional implication and incidence, is a risk factor for breast and colorectal cancer.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Rokavec, W. Schroth, S. M.C. Amaral, P. Fritz, L. Antoniadou, D. Glavac, W. Simon, M. Schwab, M. Eichelbaum, and H. Brauch
A Polymorphism in the TC21 Promoter Associates with an Unfavorable Tamoxifen Treatment Outcome in Breast Cancer
Cancer Res., December 1, 2008; 68(23): 9799 - 9808.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. W. Neklason, R. A. Kerber, D. B. Nilson, H. Anton-Culver, A. G. Schwartz, C. A. Griffin, J. T. Lowery, J. M. Schildkraut, J. P. Evans, G. E. Tomlinson, et al.
Common Familial Colorectal Cancer Linked to Chromosome 7q31: A Genome-Wide Analysis
Cancer Res., November 1, 2008; 68(21): 8993 - 8997.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.